title: [Ovariopexy and the treatment of Hodgkin's disease].
abstract: Between 1979 and 1989 a total of 113 women underwent treatment for Hodgkin's disease at the Department of Radiation Oncology of the University of Erlangen-Nürnberg. Only 17 female patients of child bearing age received total lymphoid irradiation including pelvic and inguinal nodes. 15/17 patients underwent prophylactic bilateral oophoropexy during staging laparotomy: ten had lateral, five had midline ovarian transposition. Reproductive and ovarian function was investigated in 13 patients--all in complete remission after a minimum follow-up of three years--by menstrual history and serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), testosterone, dehydroepiandrosteronsulfate (DHEAS), androstendion, estradiol, progesterone, 17-OH progesterone, sexual hormone binding globulin (SHBG), free androgen index (FAI). Thyroid function was assessed by measuring thyroxine (T4), triiodothyronine (T3), thyroxine stimulating hormone (TSH) and thyroxine binding globulin (TBG). Normal cyclic ovarian activity was found in seven out of nine patients following lateral oophoropexy (including one pregnancy), but only in one out of four cases after midline fixation. Median calculated dose was 325 cGy (range 260 to 500 cGy) to the laterally fixed ovaries and 490 cGy (range 390 to 500 cGy) for midline transposition. We conclude, if ovarian protection is required prior to pelvic radiation, lateral oophoropexy should be preferred.
authors.affiliation: Strahlentherapeutische Klinik, Universität Erlangen-Nürnberg.
authors.forename: G G
authors.initials: GG
authors.lastname: Grabenbauer
authors.forename: P
authors.initials: P
authors.lastname: Girke
authors.forename: L
authors.initials: L
authors.lastname: Wildt
authors.forename: R G
authors.initials: RG
authors.lastname: Müller
authors.forename: M
authors.initials: M
authors.lastname: Herbst
authors.forename: R
authors.initials: R
authors.lastname: Sauer
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications / Q000532:radiotherapy*; D006801:Humans; D015182:Lymphatic Irradiation / Q000009:adverse effects; D010049:Ovarian Diseases / Q000453:epidemiology / Q000517:prevention & control; D010053:Ovary / Q000528:radiation effects / Q000601:surgery*; D011832:Radiation Injuries / Q000453:epidemiology / Q000517:prevention & control; D011835:Radiation Protection / Q000379:methods*; D011879:Radiotherapy Dosage
vernacular_title: Ovaropexie und die Behandlung des Morbus Hodgkin.